Significance of the enhancement of GABA receptor binding with low affinity in the assessment of central effects of benzodiazepine derivatives: Analysis using a 1H-1,2,4-triazolyl benzophenone derivative (450191-S).
The central actions of 1-(2-o-chlorobenzoyl-4-chlorophenyl)-5-glycylaminomethyl-3-dimethylcarbamoyl-1H-1,2,4-triazole hydrochloride dihydrate (450191-S), a potent sleep-inducing and anxiolytic drug, were re-evaluated in terms of the affinity for benzodiazepine (BZP) receptor and the activation of ?-aminobutyric acid (GABA) receptor binding. The 450191-S showed only very low capacity to displace the bindings of [(3)H]diazepam, [(3)H]?-carboline-3-carboxylate-ethylester, [(3)H]Rol5-1788, [(3)H]Ro5-4864 and [(3)H]naloxone to cerebral synaptic membranes. Similarly, this drug had a weak and undistinguishable affinity to both BZPtype 1 and 2 receptors determined under the presence of CL 218,872. On the other hand, 450191-S as well as its active metabolites (M-1, M-2, M-A, M-3 and M-4) showed a remarkable activating effect on the GABA receptor binding with low affinity in cerebral synaptic membranes. This enhancement of the low affinity GABA receptor binding was found to be due to the increase of affinity (K(d)) but not to the change in B(max). Furthermore, it has been found that the observed accentuation of low affinity GABA receptor binding is well-correlated with the potency of the central actions of 450191-S such as potentiation of the hypnotic action of barbiturates and muscle relaxation. These results suggest that the central actions of 450191-S may be due to, at least in part, the activation of central GABA receptor binding with low affinity. The present results also suggest that the activation of low affinity GABA receptor binding may be a better criterion than the affinity of BZP receptor for elucidating the central action of a certain type of BZP derivatives.